Clinical impact of multidrug-resistant organisms in liver cirrhosis: A retrospective cohort study in the intensive care setting

Table 2 Multidrug-resistant organism species identified in colonization and infection episodes at intensive care unit admission, n (%)

MDRO species	Total (n)	Colonized	Infected	P value1
MDR A. baumanii	29	8 (21.1)	21 (37.5)	0.142
Escherichia coli, ESBL	2	0 (0.0)	2 (3.6)	0.513
Escherichia coli, ESBL and OXA-48	1	0 (0.0)	1 (1.8)	1
Klebsiella oxytoca, OXA-48	1	1 (2.6)	0 (0.0)	0.404
Klebsiella pneumoniae, ESBL	3	1 (2.6)	2 (3.6)	1
Klebsiella pneumoniae, ESBL and OXA-48	5	3 (7.9)	2 (3.6)	0.391
Klebsiella pneumoniae, KPC	3	1 (2.6)	2 (3.6)	1
Klebsiella pneumoniae, OXA-48	19	8 (21.1)	11 (19.6)	0.925
MDR Pseudomonas spp.	2	2 (5.3)	0 (0.0)	0.161
VRE	10	4 (10.5)	6 (10.7)	1
MRSA	19	10 (26.3)	9 (16.1)	0.341

¹P values were calculated using Fisher’s exact test.

MDRO: Multidrug-resistant organism; A. baumanii: Acinetobacter baumannii; ESBL: Extended-spectrum beta-lactamase; OXA-48: Oxacillinase-48; KPC: Klebsiella pneumoniae carbapenemase; MDR: Multidrug-resistant; VRE: Vancomycin-resistant Enterococcus spp.; MRSA: Methicillin-resistant Staphylococcus aureus.